Display Settings:

Format

Send to:

Choose Destination
    Future Microbiol. 2010 Feb;5(2):221-39.

    Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.

    Source

    Vaccine Discovery, La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA. mmoutaftsi@idri.org

    Abstract

    Vaccinia virus (VACV) was used as the vaccine strain to eradicate smallpox. VACV is still administered to healthcare workers or researchers who are at risk of contracting the virus, and to military personnel. Thus, VACV represents a weapon against outbreaks, both natural (e.g., monkeypox) or man-made (bioterror). This virus is also used as a vector for experimental vaccine development (cancer/infectious disease). As a prototypic poxvirus, VACV is a model system for studying host-pathogen interactions. Until recently, little was known about the targets of host immune responses, which was likely owing to VACVs large genome (>200 open reading frames). However, the last few years have witnessed an explosion of data, and VACV has quickly become a useful model to study adaptive immune responses. This review summarizes and highlights key findings based on identification of VACV antigens targeted by the immune system (CD4, CD8 and antibodies) and the complex interplay between responses.

    PMID:
    20143946
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3363998

    Images from this publication.See all images (2) Free text

    Figure 1
    Figure 2

      Supplemental Content

      Icon for Atypon

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk